ASID/TSANZ guidelines: Treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents

Allen Cheuk-Seng Cheng, Dominic E Dwyer, Tom C Kotsimbos, Michael Starr, Tony Korman, James Peter Buttery, Christine R Jenkins, Vicki L Krause, Paul D R Johnson

Research output: Contribution to journalArticleOther

Abstract

To date, there have been thousands of cases of H1N1 influenza 09 (human swine influenza) worldwide, with established community transmission in parts of Australia. Timely diagnostic tests can enable targeted antiviral treatment early in the course of the pandemic. Rapid antigen tests will be less useful once the pandemic is established. Recommendations for use of antiviral treatment for influenza: Neuraminidase inhibitors (oseltamivir and zanamivir) are the antiviral agents of choice for H1N1 influenza 09. In otherwise healthy children and adults with confirmed or suspected influenza, antiviral treatment is of greatest benefit when given within 48 hours of symptom onset. Treatment should be prioritised for patients with risk factors for severe disease, such as older people (> 65 years), pregnant women, patients with chronic disease (eg, asthma, cardiorespiratory disease, diabetes and renal failure) or immunosuppression, and young children. Antiviral treatment can be given to children as young as 1 year. However, animal studies suggest central nervous system accumulation of oseltamivir in infants <1 year. Parents should be informed of the possibility of uncommon neuropsychiatric adverse events among children.......
Original languageEnglish
Pages (from-to)1 - 8
Number of pages8
JournalMedical Journal of Australia
Volume191
Publication statusPublished - 2009

Cite this

@article{4cc73ffb42e745f2a5d22e0edc712e2d,
title = "ASID/TSANZ guidelines: Treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents",
abstract = "To date, there have been thousands of cases of H1N1 influenza 09 (human swine influenza) worldwide, with established community transmission in parts of Australia. Timely diagnostic tests can enable targeted antiviral treatment early in the course of the pandemic. Rapid antigen tests will be less useful once the pandemic is established. Recommendations for use of antiviral treatment for influenza: Neuraminidase inhibitors (oseltamivir and zanamivir) are the antiviral agents of choice for H1N1 influenza 09. In otherwise healthy children and adults with confirmed or suspected influenza, antiviral treatment is of greatest benefit when given within 48 hours of symptom onset. Treatment should be prioritised for patients with risk factors for severe disease, such as older people (> 65 years), pregnant women, patients with chronic disease (eg, asthma, cardiorespiratory disease, diabetes and renal failure) or immunosuppression, and young children. Antiviral treatment can be given to children as young as 1 year. However, animal studies suggest central nervous system accumulation of oseltamivir in infants <1 year. Parents should be informed of the possibility of uncommon neuropsychiatric adverse events among children.......",
author = "Cheng, {Allen Cheuk-Seng} and Dwyer, {Dominic E} and Kotsimbos, {Tom C} and Michael Starr and Tony Korman and Buttery, {James Peter} and Jenkins, {Christine R} and Krause, {Vicki L} and Johnson, {Paul D R}",
year = "2009",
language = "English",
volume = "191",
pages = "1 -- 8",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",

}

ASID/TSANZ guidelines: Treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents. / Cheng, Allen Cheuk-Seng; Dwyer, Dominic E; Kotsimbos, Tom C; Starr, Michael; Korman, Tony; Buttery, James Peter; Jenkins, Christine R; Krause, Vicki L; Johnson, Paul D R.

In: Medical Journal of Australia, Vol. 191, 2009, p. 1 - 8.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - ASID/TSANZ guidelines: Treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents

AU - Cheng, Allen Cheuk-Seng

AU - Dwyer, Dominic E

AU - Kotsimbos, Tom C

AU - Starr, Michael

AU - Korman, Tony

AU - Buttery, James Peter

AU - Jenkins, Christine R

AU - Krause, Vicki L

AU - Johnson, Paul D R

PY - 2009

Y1 - 2009

N2 - To date, there have been thousands of cases of H1N1 influenza 09 (human swine influenza) worldwide, with established community transmission in parts of Australia. Timely diagnostic tests can enable targeted antiviral treatment early in the course of the pandemic. Rapid antigen tests will be less useful once the pandemic is established. Recommendations for use of antiviral treatment for influenza: Neuraminidase inhibitors (oseltamivir and zanamivir) are the antiviral agents of choice for H1N1 influenza 09. In otherwise healthy children and adults with confirmed or suspected influenza, antiviral treatment is of greatest benefit when given within 48 hours of symptom onset. Treatment should be prioritised for patients with risk factors for severe disease, such as older people (> 65 years), pregnant women, patients with chronic disease (eg, asthma, cardiorespiratory disease, diabetes and renal failure) or immunosuppression, and young children. Antiviral treatment can be given to children as young as 1 year. However, animal studies suggest central nervous system accumulation of oseltamivir in infants <1 year. Parents should be informed of the possibility of uncommon neuropsychiatric adverse events among children.......

AB - To date, there have been thousands of cases of H1N1 influenza 09 (human swine influenza) worldwide, with established community transmission in parts of Australia. Timely diagnostic tests can enable targeted antiviral treatment early in the course of the pandemic. Rapid antigen tests will be less useful once the pandemic is established. Recommendations for use of antiviral treatment for influenza: Neuraminidase inhibitors (oseltamivir and zanamivir) are the antiviral agents of choice for H1N1 influenza 09. In otherwise healthy children and adults with confirmed or suspected influenza, antiviral treatment is of greatest benefit when given within 48 hours of symptom onset. Treatment should be prioritised for patients with risk factors for severe disease, such as older people (> 65 years), pregnant women, patients with chronic disease (eg, asthma, cardiorespiratory disease, diabetes and renal failure) or immunosuppression, and young children. Antiviral treatment can be given to children as young as 1 year. However, animal studies suggest central nervous system accumulation of oseltamivir in infants <1 year. Parents should be informed of the possibility of uncommon neuropsychiatric adverse events among children.......

UR - http://www.mja.com.au/public/rop/cheng/che10661_fm.pdf

M3 - Article

VL - 191

SP - 1

EP - 8

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

ER -